Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease
Authors:
- 1 February 2014
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 146 (2) , 383-391
Abstract
No abstract availableKeywords
Funding Information
- Crohn's and Colitis Foundation of America
This publication has 17 references indexed in Scilit:
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2012
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Growth Abnormalities Persist in Newly Diagnosed Children With Crohn Disease Despite Current Treatment ParadigmsJournal of Pediatric Gastroenterology and Nutrition, 2009
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007
- Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006
- Prolonged duration of response to infliximab in early but not late pediatric Crohn's diseaseAmerican Journal of Gastroenterology, 2000
- A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's diseaseGastroenterology, 2000
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983